

Koji Sasaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5759175/publications.pdf>

Version: 2024-02-01

320
papers

6,872
citations

71061

41
h-index

85498

71
g-index

326
all docs

326
docs citations

326
times ranked

5313
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
2	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	5.1	245
3	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , the, 2015, 2, e186-e193.	2.2	227
4	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e724-e736.	2.2	201
5	Impact of complete molecular response on survival in patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 504-507.	0.6	194
6	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 240-248.	5.1	192
7	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , the, 2018, 5, e618-e627.	2.2	190
8	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
9	Hyper-“CVAD plus ponatinib versus hyper-“CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-“positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	2.0	156
10	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
11	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017, 130, 1514-1522.	0.6	151
12	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
13	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-“Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	3.4	124
14	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
15	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	2.0	114
16	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
17	Malignancy-“associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	2.0	88
18	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-“hyper-“CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-“negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	2.0	88

#	ARTICLE	IF	CITATIONS
19	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	2.5	88
20	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
21	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	2.5	84
22	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. <i>Haematologica</i> , 2021, 106, 894-898.	1.7	80
23	Outcomes of TP53 mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80
24	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	2.0	79
25	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70
26	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	2.0	69
27	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66
28	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , 2015, 2, e118-e128.	2.2	65
29	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	0.6	65
30	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVAD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
31	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
32	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
33	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	0.7	53
34	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	3.4	53
35	Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. <i>American Journal of Hematology</i> , 2021, 96, 650-658.	2.0	52
36	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2092-2097.	0.6	51

#	ARTICLE	IF	CITATIONS
37	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	2.0	51
38	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
39	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	2.8	49
40	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	0.6	48
41	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	1.7	46
42	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
43	Outcome of Philadelphia cell acute lymphoblastic leukemia/lymphoma: Focus on Philadelphia phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	2.0	42
44	Poor outcomes associated with +der(22)t(9;22) and t(9;9p) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41
45	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
46	Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	2.0	40
47	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
48	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , 2019, 134, 830-830.	0.6	38
49	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	2.0	37
50	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	2.0	35
51	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
52	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
53	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	2.0	34
54	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. <i>Frontiers in Oncology</i> , 2020, 10, 582213.	1.3	33
56	Prognostic factors for progression in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	2.0	33
57	Free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	2.0	33
58	Hypomethylating agent and venetoclax with FLT3 inhibitor –triple–therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
59	Prognostic significance of baseline FLT3–TD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
60	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32
61	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	2.0	31
62	Venetoclax combined with FLAG–IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
63	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2016, 122, 238-248.	2.0	30
64	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. <i>International Journal of Hematology</i> , 2013, 98, 702-707.	0.7	26
65	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2019, 134, 678-678.	0.6	26
66	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
67	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.2	25
68	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	0.7	25
69	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia–negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
70	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	2.0	25
71	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	1.2	24
72	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24

#	ARTICLE	IF	CITATIONS
73	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	2.0	23
74	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 872-881.	3.3	22
75	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 48.	2.8	22
76	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (IFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22
77	Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 3807-3807.	0.6	21
78	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	2.8	20
79	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
91	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. Journal of Clinical Oncology, 2017, 35, 7013-7013.	0.8	18
92	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer, 2016, 122, 3812-3820.	2.0	17
93	Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 696-696.	0.6	17
94	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. Blood, 2018, 132, 553-553.	0.6	17
95	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2020, 136, 18-20.	0.6	17
96	A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood, 2020, 136, 7-9.	0.6	17
97	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Advances, 2022, 6, 3027-3035.	2.5	17
98	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 813-820.	0.6	16
99	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689.	2.9	16
100	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	3.3	16
101	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer, 2022, , .	2.0	16
102	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leukemia and Lymphoma, 2019, 60, 442-452.	0.6	15
103	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	2.0	15
104	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	0.6	15
105	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica, 2021, 106, 2853-2858.	1.7	15
106	Improved outcomes among newly diagnosed patients with <sc>FMS-like tyrosine kinase 3 internal tandem duplication</sc> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	2.0	15
107	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer, 2016, 122, 3336-3343.	2.0	14
108	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 1493-1499.	0.6	14

#	ARTICLE	IF	CITATIONS
109	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2018, 132, 32-32.	0.6	14
110	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	0.6	13
111	Modified <sc>CVAD</sc> and modified <sc>CBAD</sc> compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 388-392.	1.1	12
112	Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <i>Leukemia and Lymphoma</i> , 2020, 61, 3120-3127.	0.6	12
113	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3402-3410.	0.6	12
114	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	0.6	12
115	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 823-823.	0.6	12
116	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2640-2640.	0.6	12
117	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7041-7041.	0.8	12
118	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	2.0	12
119	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	0.6	12
120	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 616-624.	0.2	11
121	Current status and novel strategy of CML. <i>International Journal of Hematology</i> , 2021, 113, 624-631.	0.7	11
122	Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 232-232.	0.6	11
123	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	0.6	11
124	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 1641-1641.	0.6	11
125	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2019, 134, 3806-3806.	0.6	11
126	Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 359-359.	0.6	11

#	ARTICLE	IF	CITATIONS
127	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	0.6	11
128	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 588-588.	0.6	11
129	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	11
130	A Single Case of Rosai-Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. <i>Frontiers in Oncology</i> , 2014, 4, 297.	1.3	10
131	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. <i>American Journal of Hematology</i> , 2019, 94, 74-79.	2.0	10
132	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	2.0	10
133	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
134	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	2.0	10
135	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19.	0.6	10
136	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. <i>Acta Haematologica</i> , 2021, 144, 285-292.	0.7	10
137	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
138	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. <i>Modern Pathology</i> , 2022, 35, 1212-1219.	2.9	10
139	Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan. <i>Journal of Radiation Research</i> , 2020, 61, 104-116.	0.8	9
140	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<sc>MDS/MPN</sc>) and myelodysplastic syndrome with ring sideroblasts (<sc>MDS</sc>). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	2.0	9
141	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
142	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3810-3810.	0.6	9
143	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	3.3	9
144	Analysis of modulation factor to shorten the delivery time in helical tomotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 83-87.	0.8	8

#	ARTICLE	IF	CITATIONS
145	Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. American Journal of Hematology, 2017, 92, E595-E597.	2.0	8
146	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	2.0	8
147	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1295-1295.	0.6	8
148	Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S375-S376.	2.0	7
149	Interfacility variation in treatment planning parameters in tomotherapy: field width, pitch, and modulation factor. Journal of Radiation Research, 2018, 59, 664-668.	0.8	7
150	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 338-344.	0.2	7
151	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, .	2.0	7
152	Development of twist-correction system for radiotherapy of head and neck cancer patients. Journal of Applied Clinical Medical Physics, 2019, 20, 128-134.	0.8	6
153	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
154	Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 1312-1312.	0.6	6
155	Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 2783-2783.	0.6	6
156	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica, 2021, 106, 0-0.	1.7	6
157	Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood, 2020, 136, 25-26.	0.6	6
158	TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012.	2.0	6
159	Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers, 2022, 14, 2533.	1.7	6
160	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10^{-4} and higher. American Journal of Hematology, 2022, 97, 1135-1141.	2.0	6
161	Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S171.	0.2	5
162	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica, 2016, 101, e324-e327.	1.7	5

#	ARTICLE	IF	CITATIONS
163	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5
164	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	2.8	5
165	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	2.0	5
166	Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. <i>Blood</i> , 2018, 132, 5513-5513.	0.6	5
167	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4017-4017.	0.6	5
168	Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3819-3819.	0.6	5
169	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. <i>Blood</i> , 2019, 134, 1656-1656.	0.6	5
170	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. <i>Blood</i> , 2019, 134, 3016-3016.	0.6	5
171	Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 2289-2289.	0.6	5
172	Type I interferon upregulation and deregulation of genes involved in monoopoiesis in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2021, 101, 106511.	0.4	4
173	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. <i>Blood</i> , 2018, 132, 34-34.	0.6	4
174	Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , 2019, 134, 1296-1296.	0.6	4
175	The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2019, 134, 1642-1642.	0.6	4
176	The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1436-1436.	0.6	4
177	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 5277-5277.	0.6	4
178	Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016, 128, 940-940.	0.6	4
179	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	2.0	4
180	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4

#	ARTICLE	IF	CITATIONS
181	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2015, 5, 29.	1.3	3
182	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. <i>Acta Haematologica</i> , 2021, 144, 585-590.	0.7	3
183	Lung dose reduction in patients with stage III non-small-cell lung cancer using software that estimates patient-specific dose reduction feasibility. <i>Physica Medica</i> , 2021, 85, 57-62.	0.4	3
184	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 34-34.	0.6	3
185	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2016, 128, 226-226.	0.6	3
186	Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7036-7036.	0.8	3
187	Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7033-7033.	0.8	3
188	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 2577-2577.	0.6	3
189	Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2020, 136, 42-44.	0.6	3
190	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1714-1717.	0.6	3
191	High-grade neuroendocrine carcinoma of the bladder (large cell and small cell mixed): a literature review and case report of a rare bladder tumor. <i>International Cancer Conference Journal</i> , 2015, 4, 249-253.	0.2	2
192	Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S256-S257.	0.2	2
193	A Relationship Between Cervical Vertebrae Twisting and Cranial Angle in Head and Neck Radiotherapy. <i>In Vivo</i> , 2020, 34, 2401-2406.	0.6	2
194	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	2.0	2
195	Examination of the best head tilt angle to reduce the parotid gland dose maintaining a safe level of lens dose in whole-brain radiotherapy using the four-field box technique. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 49-57.	0.8	2
196	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 61-68.	1.2	2
197	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	2
198	Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1548-1548.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. <i>Blood</i> , 2018, 132, 3983-3983.	0.6	2
200	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2019, 134, 2642-2642.	0.6	2
201	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1715-1715.	0.6	2
202	Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. <i>Blood</i> , 2020, 136, 36-37.	0.6	2
203	Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-25.	0.6	2
204	Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
205	Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents. <i>Blood</i> , 2020, 136, 1-3.	0.6	2
206	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2020, 136, 32-34.	0.6	2
207	Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4640-4640.	0.6	2
208	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 964-964.	0.6	2
209	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. <i>Blood</i> , 2015, 126, 1298-1298.	0.6	2
210	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. <i>Blood</i> , 2016, 128, 3975-3975.	0.6	2
211	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 757-757.	0.6	2
212	Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7024-7024.	0.8	2
213	Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7014-7014.	0.8	2
214	Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3013-3013.	0.6	2
215	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2021, 138, 1480-1480.	0.6	2
216	Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. <i>Blood</i> , 2020, 136, 40-41.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. <i>Blood</i> , 2020, 136, 18-19.	0.6	2
218	Rotational output and beam quality evaluations for helical tomotherapy with use of a third-party quality assurance tool. <i>Radiological Physics and Technology</i> , 2016, 9, 53-59.	1.0	1
219	Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S257-S258.	0.2	1
220	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S193-S194.	0.2	1
221	Impact of treatment planning using a structure block function on the target and organ doses related to patient movement in cervical esophageal cancer: A phantom study. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 75-83.	0.8	1
222	Dosimetric effects of dose calculation grid size on the epidural space dose. <i>Medical Dosimetry</i> , 2020, 45, 327-333.	0.4	1
223	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. <i>Blood</i> , 2018, 132, 2674-2674.	0.6	1
224	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. <i>Blood</i> , 2020, 136, 38-40.	0.6	1
225	Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2020, 136, 21-22.	0.6	1
226	Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories. <i>Blood</i> , 2020, 136, 8-9.	0.6	1
227	Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. <i>Blood</i> , 2014, 124, 4666-4666.	0.6	1
228	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. <i>Blood</i> , 2014, 124, 534-534.	0.6	1
229	Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. <i>Blood</i> , 2015, 126, 1335-1335.	0.6	1
230	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 2877-2877.	0.6	1
231	Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2015, 126, 3756-3756.	0.6	1
232	Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities. <i>Blood</i> , 2015, 126, 598-598.	0.6	1
233	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. <i>Blood</i> , 2016, 128, 3166-3166.	0.6	1
234	Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7025-7025.	0.8	1

#	ARTICLE	IF	CITATIONS
235	Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7042-7042.	0.8	1
236	A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7111-7111.	0.8	1
237	Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood, 2014, 124, 1801-1801.	0.6	1
238	Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Blood, 2014, 124, 4538-4538.	0.6	1
239	Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 2941-2941.	0.6	1
240	Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). Blood, 2019, 134, 2578-2578.	0.6	1
241	Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R. Blood, 2020, 136, 36-37.	0.6	1
242	Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort. Blood, 2020, 136, 44-45.	0.6	1
243	Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Blood, 2020, 136, 18-19.	0.6	1
244	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 23-25.	0.6	1
245	Nilotinib or Dasatinib Front-Line Therapy in Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-existing Liver and/or Renal dysfunction. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S138-S139.	0.2	0
246	Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S202-S203.	2.0	0
247	Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S172-S173.	0.2	0
248	Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S181-S182.	0.2	0
249	Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, S228-S229.	2.0	0
250	A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S264-S265.	0.2	0
251	Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S266.	0.2	0
252	Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S255-S256.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Reply to Miniâ€HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3891-3892.	2.0	0
254	Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S181.	0.2	0
255	Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186-S187.	0.2	0
256	The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180.	0.2	0
257	Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180-S181.	0.2	0
258	Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S185.	0.2	0
259	Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186.	0.2	0
260	LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S341.	0.2	0
261	Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8040-8040.	0.8	0
262	Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. <i>Blood</i> , 2013, 122, 1500-1500.	0.6	0
263	Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. <i>Blood</i> , 2014, 124, 2273-2273.	0.6	0
264	Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2014, 124, 4641-4641.	0.6	0
265	Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. <i>Blood</i> , 2014, 124, 2288-2288.	0.6	0
266	Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. <i>Blood</i> , 2014, 124, 1924-1924.	0.6	0
267	Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). <i>Blood</i> , 2014, 124, 1922-1922.	0.6	0
268	Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. <i>Blood</i> , 2015, 126, 2496-2496.	0.6	0
269	Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 2508-2508.	0.6	0
270	Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. <i>Blood</i> , 2015, 126, 4874-4874.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. Blood, 2015, 126, 4873-4873.	0.6	0
272	The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3771-3771.	0.6	0
273	Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood, 2015, 126, 3722-3722.	0.6	0
274	Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood, 2015, 126, 3720-3720.	0.6	0
275	The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. Blood, 2015, 126, 1369-1369.	0.6	0
276	Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7038-7038.	0.8	0
277	Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7034-7034.	0.8	0
278	Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7035-7035.	0.8	0
279	Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood, 2016, 128, 1737-1737.	0.6	0
280	Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood, 2016, 128, 5194-5194.	0.6	0
281	Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2016, 128, 1224-1224.	0.6	0
282	Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood, 2016, 128, 1220-1220.	0.6	0
283	Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 1814-1814.	0.6	0
284	Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood, 2018, 132, 1514-1514.	0.6	0
285	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 4359-4359.	0.6	0
286	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2018, 132, 2664-2664.	0.6	0
287	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. Blood, 2018, 132, 1417-1417.	0.6	0
288	Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2018, 132, 2791-2791.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2695-2695.	0.6	0
290	Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1820-1820.	0.6	0
291	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). <i>Blood</i> , 2019, 134, 287-287.	0.6	0
292	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. <i>Blood</i> , 2019, 134, 1297-1297.	0.6	0
293	Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 3006-3006.	0.6	0
294	The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). <i>Blood</i> , 2019, 134, 3815-3815.	0.6	0
295	Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 1720-1720.	0.6	0
296	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 5438-5438.	0.6	0
297	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1719-1719.	0.6	0
298	Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1711-1711.	0.6	0
299	Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. <i>Blood</i> , 2019, 134, 647-647.	0.6	0
300	Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. <i>Blood</i> , 2019, 134, 2930-2930.	0.6	0
301	A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). <i>Blood</i> , 2019, 134, 4237-4237.	0.6	0
302	Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothed Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 21-23.	0.6	0
303	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. <i>Blood</i> , 2020, 136, 40-42.	0.6	0
304	Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2020, 136, 54-56.	0.6	0
305	Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
306	Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020, 136, 50-51.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020, 136, 26-29.	0.6	0
308	Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. <i>Blood</i> , 2020, 136, 46-48.	0.6	0
309	Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
310	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. <i>Blood</i> , 2020, 136, 2-4.	0.6	0
311	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
312	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
313	Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
314	Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
315	The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 3-5.	0.6	0
316	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
317	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
318	Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2020, 136, 3-4.	0.6	0
319	Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
320	Prediction for sustained deep molecular response for treatment-free remission. <i>Leukemia and Lymphoma</i> , 2022, 63, 5-6.	0.6	0